Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Hims & Hers Health shows impressive operating leverage and a scalable business model, with massive growth potential from new ...

Last year, Novo Nordisk petitioned the FDA to try to block ... risks – particularly with complex injectable products like Hims & Hers is advertising," he added. "The FDA says compounded drugs ...

President Trump signed the executive order shortly before 11 a.m. after a press conference in which he and top officials ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...